Medidata Study Experience

  1. A New Avenue In Breast Cancer Therapeutics 1/23/2023

    Clinical trial findings may have unlocked a groundbreaking opportunity for breast cancer patients: beneficial therapy for HER2-negative patients with HER2-directed antibody-drug conjugates.

  2. 3 Data Linkage Use Cases To Future Proof Your Clinical Trials 12/20/2022

    Discover why access to compelling and relevant evidence is crucial to drug development, safety monitoring, and improved patient outcomes. 

  3. The Future Of Data Linkage In Clinical Trial Evidence Generation 12/20/2022

    Explore key questions about the future of AI and data linkage in clinical trial evidence generation.

  4. The Regulatory Grade External Control Arm To Power Your Clinical Trials 12/9/2022

    Examine the growing role of external control arms in clinical trials, including the distinctions between control groups that use real-world data and those that use historical clinical trial data.

  5. Imunon Phase IB Ovarian Cancer Study Shows Strong Progression-Free Survival Treatment Effect Using A Synthetic Control Arm 12/8/2022

    Explore how Imunon used a control arm among stage III/IV ovarian cancer patients in their clinical trial.

  6. A Mid-Sized Sponsor Increased Site Count By 50% In A Rare Disease Clinical Trial 12/8/2022

    In this case study, explore how a mid-sized sponsor chose high-performing sites based on reliable data to set their trial up for success.

  7. Medicenna Gains Precedent-Setting FDA Approval 12/8/2022

    Learn how Medicenna was able to leverage Synthetic Control Arm (SCA) to bolster Phase 2 findings and gain FDA approval to design a hybrid external control arm for their Phase 3 registrational trial.

  8. Synthetic Control Arm In Clinical Trials 12/8/2022

    Get an overview of the SCA, an external control generated with the goal of improving the interpretation of uncontrolled trials, which can enable better product development decisions.

  9. Glioblastoma Multiforme 11/15/2022

    Medidata AI’s Synthetic Control Arm® (SCA®) leverages historical clinical trial data (HCTD) to provide a more relevant clinical insight for the purpose of developing new therapies.

  10. Using Data To Accelerate Racial Diversity In US Clinical Trials 11/2/2022

    Historically, US clinical trials have been shown to recruit disproportionately large percentages of White patients, raising concerns about the generalizability of clinical trial results to underrepresented racial minority patient populations. Because of this, the FDA has recently reiterated its guidance stating that clinical trials need to reflect the demographic distribution of the US.